NEC CORP ORD
Apertura: | - |
Variazione: | - |
Volumi: | - |
Minimo: | - |
Massimi: | - |
Distanza Mas/Min: | - |
Tipologia: | Azioni |
Ticker: | NIPNF |
ISIN: | JP3733000008 |
NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines
- 66
TOKYO, Apr 8, 2024 - (JCN Newswire) - NEC Corporation (TSE: 6701) has released a white paper, "Towards the realization of AI drug development: Comprehensive process workflow for the commercial use of personalized cancer vaccines". This white paper introduces (1) a comprehensive process workflow that can be applied to a wide range of processes, starting from tumor sample collection to vaccine design, manufacturing, supply, and administration, (2) important perspectives for consideration in the workflow, and (3) advanced technologies that will contribute to the realization of the workflow.
Click here for details and downloads (registration is not required)URL: www.nec.com/en/global/solutions/ai-drug/publication/index.html
NEC is committed to taking on the challenge of realizing new cancer treatments by aiming to establish an accurate, reliable, and comprehensive process workflow that utilizes AI and security technologies.
In recent years, there have been growing expectations for personalized neoantigen cancer vaccines as a next-generation cancer therapy. Personalized neoantigen cancer vaccines are a type of cancer immunotherapy that targets neoantigens containing genomic mutations that are specific to each patient. NEC is working on the realization of personalized cancer vaccines by using one of its core technologies, AI, to identify target neoantigens from each individual patient's genome data.
This white paper proposes a comprehensive process workflow for personalized cancer vaccines, from design to administration, and the perspectives that should be discussed in this flow. Furthermore, NEC's advanced ICT technologies are introduced to address these perspectives, and the possibility that the use of ICT technology will contribute to the realization of a platform for not only personalized cancer vaccines, but also for various cancer treatments are discussed.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.
Source: NEC Corporation
Copyright 2024 JCN Newswire . All rights reserved.
JCN Newswire
JCN Newswire is an associate company of ACN Newswire, which established ACN Newswire, a press release distributor for Asian companies and organizations, in 2001.
Global press release distribution and financial disclosure; Direct distribution to financial terminals, desktops and financial media; English, Chinese, Korean and Japanese press release translation and distribution